EP0983067A1 - Benzimidazole pharmaceutical composition and process of preparation - Google Patents

Benzimidazole pharmaceutical composition and process of preparation

Info

Publication number
EP0983067A1
EP0983067A1 EP98922927A EP98922927A EP0983067A1 EP 0983067 A1 EP0983067 A1 EP 0983067A1 EP 98922927 A EP98922927 A EP 98922927A EP 98922927 A EP98922927 A EP 98922927A EP 0983067 A1 EP0983067 A1 EP 0983067A1
Authority
EP
European Patent Office
Prior art keywords
benzimidazole
moisture resistant
resistant coating
core
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98922927A
Other languages
German (de)
French (fr)
Inventor
Yusuf Khwaja-Windsor Villa Hamied
Vinay G. Nayak
Geena Malhotra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of EP0983067A1 publication Critical patent/EP0983067A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Definitions

  • the present invention relates to a pharmaceutical composition and to a process of preparation thereof, and more particularly to a pharmaceutical composition containing a benzimidazole.
  • Benzirnidazole derivatives such as omeprazole, lansoprazole and timoprazole, etc.
  • omeprazole lansoprazole
  • timoprazole timoprazole
  • Benzirnidazole derivatives are known potent proton pump inhibitors with powerful inhibitory action against the secretion of gastric acid (Lancet, Nov. 27, 1982, pages 1223 - 1224). They are used in the treatment of Zollinger- Ellison syndrome and stress related oesophagitis ulceration.
  • the derivatives are well known and are described, for example, in EP-A-0005129.
  • EP-A-0247983 describes an oral pharmaceutical preparation of omeprazole which is composed of a core material in the form of small beads or tablets containing omeprazole together with an alkaline reacting compound, the core material having one or more inert reacting subcoating layers thereon.
  • the alkaline reacting compounds can be chosen among but are not restricted to substances such as the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids; substances normally used in antacid preparations such as alurriinium, calcium and magnesium hydroxides; magnesium oxide or composite substances, such as Al 2 0 3 .6MgO.C0 2 .12H 2 0, (Mg 6 Al 2 (OH) 16 C0 3 .4H 2 0), MgO.Al 2 0 3 .2Si0 2 .nH 2 0 or similar compounds; organic pH-buffering substances such as trmydroxymethylaminomethane or other similar, pharmaceutically acceptable pH-buffering substances.
  • substances such as the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids
  • substances normally used in antacid preparations such as alurriin
  • alkaline reacting salt of omeprazole such as the sodium, potassium, magnesium, calcium or ammonium salt of omeprazole (which are described in EP-A-0124495) is used, this can be in place of or in addition to the alkaline reacting compound.
  • TW289733 describes a process of preparing pellets containing omeprazole.
  • the process comprises spraying a solution comprising omeprazole, excipient, ethanol, water, ammonia and binder on an inert core; granulating; spraying an intermediate coating solution comprising excipient, ethanol, water, ammonia and binder on the granules; and providing a final outer coating.
  • US4786505 describes pharmaceutical preparations containing omeprazole in an alkali environment as the core material, one or more inert subcoating layers which are water soluble and an outer enteric coating.
  • compositions which is a solid pellet comprising an inert core, a benzimidazole in or on the core, a moisture resistant coating around the core, the moisture resistant coating comprising at least one hydrophobic material, and an enteric coating around the moisture resistant coating.
  • a process of preparing a composition substantially as described above comprises providing an inert core having a benzimidazole therein or thereon, applying a moisture resistant coating around the core, the moisture resistant coating comprising at least one hydrophobic material, and applying an enteric coating around the moisture resistant coating.
  • the benzimidazole in or on the core is present in an alkaline environment, and more particularly the benzimidazole is present as an intimate mixture with at least one alkali.
  • the alkali is ammonia or a solution of ammonia or ammonium carbonate.
  • a process according to the present invention therefore preferably further comprises formulating the benzimidazole in an alkaline environment substantially as herein described.
  • an alkali employed in the present invention comprises an aqueous solution of ammonia (i.e. ammonium hydroxide) or ammonium carbonate, although it is of course also possible to use liquid ammonia or ammonia gas.
  • the benzimidazole may be formulated under an ammonia atmosphere, for example, and the gas may be absorbed, such as by dissolution in any aqueous material present.
  • the pH of the benzimidazole- containing part of any formulation is preferably from above 7 to 10, and is more preferably in the range 8 to 9.
  • an ammonia solution is used, the solution preferably containing from 20 to 40wt% ammonia, more preferably about 30 wt% ammonia.
  • the invention is applicable to pharmaceutically active benzimidazole derivatives. Particularly useful such derivatives are the alkali metal salts of the benzimidazole. Examples of specific useful derivatives are omeprazole, lansoprazole, timoprazole, pariprazole and pantoprazole, in particular omeprazole.
  • the hydrophobic material of the coating is present in sufficient amount to ensure that the coating substantially repels water therefrom.
  • the hydrophobic material can be solid or liquid, and is desirably selected from the group consisting of a polyalkylsiloxane, castor oil, mineral oil, isopropyl myristate, stearic acid, cetyl alcohol or the like.
  • the hydrophobic material comprises a polyalkylsiloxane, and it is particularly preferred that the hydrophobic material comprises polydimethylsiloxane.
  • the moisture resistant coating may further comprise at least one binding agent.
  • the binding agent may be hydrophobic or hydrophilic. In the latter case, the binding agent is incorporated in the moisture resistant coating in an amount which ensures that the water repellent properties of the latter (as provided by the hydrophobic material substantially as described above), are substantially unaffected by the hydrophilic nature of the binding agent.
  • the binding agent is preferably selected from the group consisting of a sugar, polyvinyl-pyrrolidone, shellac and gums, such as xanthan gum, or the like. It is especially preferred that the binding agent comprises a sugar, such as sucrose or the like.
  • a binding agent is employed in the moisture resistant coating when the hydrophobic material is a liquid.
  • a preferred moisture resistant coating comprises an emulsion of a polyalkylsiloxane (especially polydimethylsiloxane) or an admixture thereof, with the binding agent.
  • the moisture resistant coating may contain one or more other conventional additives that typically aid in the process of adhesion onto the inert core.
  • the moisture resistant coating may also be useful in benzimidazole pharmaceutical compositions that do not have an alkaline binder.
  • the moisture resistant coating can be typically applied by spraying, using conventional equipment.
  • a further moisture resistant coating can be provided over the enteric coating.
  • enteric coatings may be employed in the present invention, including for example: cellulose acetate phthalate; hydroxypropyl methyl cellulose phthalate (HPMCP); hydroxypropyl cellulose acetyl succinate; polyvinyl acetate phthalate; copolymerised methacrylic acid/methacrylic acid methyl esters, such as Eudragit L 12-5, Eudragit L 100 55 or Eudragit S 100; and mixtures thereof.
  • the enteric coating may contain conventional plasticisers, pigments and/or dispersants, including for example polyethylene glycols, triacetin, triethyl citrate, and Citroflex, dibutyl sebacate.
  • the enteric coating can be applied in any suitable manner, for example in the form of an aqueous dispersion in water, or other dispersing medium, or in the form of a solution. It is preferred that a dispersion or solution of the enteric coating is treated with an alkali in order to neutralise at least part of any free acid content.
  • the alkali may be, for example, a carbonate or hydroxide of sodium, potassium, magnesium or calcium.
  • the benzimidazole is present in the inert core.
  • the inert core of the pharmaceutical composition comprises a plurality of compressed granules of the benzimidazole.
  • This embodiment is particularly useful when it is desired to provide the pharmaceutical composition in tablet form, and there is further provided by the present invention a tablet which comprises a pharmaceutical composition substantially as herein described, wherein the inert core is formed from a plurality of granules comprising the benzimidazole, which granules are compressed together to form the core.
  • the moisture resistant coating is applied around the inert core, then the enteric coating is suitably provided around the moisture resistant coating on the inert core.
  • the benzimidazole is present on the inert core.
  • the second embodiment of the present invention is particularly applicable for the inclusion of a plurality of pellets substantially as herein before described in a capsule.
  • the inert cores of the pellets may typically be non-pareils, and suitably provided in the form of sugar beads or sugar/starch beads.
  • a capsule which comprises a capsule shell containing a plurality of pellets substantially as herein before described.
  • the moisture resistant coating is applied around the inert core of each of the pellets to be provided in a capsule, and the enteric coating is suitably provided around the moisture resistant coating on each of the inert cores.
  • compositions according to the present invention may comprise one or more additives.
  • particularly useful additives include a solubiliser to aid solubilisation of the pharmaceutically active ingredient, and a lubricant to aid flow of the active ingredient during manufacture.
  • the solubiliser may be, for example, a sugar, which is preferably in pulverised form.
  • An example of a suitable sugar is sucrose.
  • the lubricant may be, for example, starch and/or talcum. It will be appreciated that the pharmaceutical compositions of the invention may contain any one or more other additives conventionally used in the formulation of pharmaceutical compositions.
  • compositions of the invention may be used to treat conditions in the same manner as the prior known benzimidazole compositions.
  • the pharmaceutical compositions may be formulated for oral, topical, parenteral or rectal administration. Oral administration is preferred.
  • the pharmaceutical compositions may take the form of, for example, a tablet or peltab (e.g. comprising a plurality of granules comprising a benzimidazole, together with conventional excipients, such as disintegrants and binders, compressed into a tablet) or a capsule (e.g. containing a plurality of individual pellets comprising a benzimidazole disposed within the capsule shell).
  • a tablet or peltab e.g. comprising a plurality of granules comprising a benzimidazole, together with conventional excipients, such as disintegrants and binders, compressed into a tablet
  • a capsule e.g. containing a plurality of individual pellets comprising a benzimidazole disposed within the capsule shell.
  • the pharmaceutical composition may include conventional excipients.
  • Tablets to be employed in compositions of the invention can be made, for example, by using equipment known as a marumerizer (which is also called a spheronizer).
  • a marumerizer which is also called a spheronizer
  • core ingredients including the benzimidazole
  • the granules may be compressed by conventional means in order to form a solid core, and subsequently coated with a moisture resistant coating and an enteric coating as herein before described.
  • the pellets comprise benzimidazole loaded onto a plurality of inert cores suitable for inclusion in a capsule
  • the benzimidazole can be supplied as a spray, for example.
  • the benzimidazole may be mixed with one or more additives before being loaded on the inert cores.
  • the additives may include, for example, a solubiliser and/or a lubricant.
  • the inert cores can be loaded with the benzimidazole (together with any additives), and sprayed with a binder, in a centrifugal coating apparatus.
  • Non-pareil seeds 95.00 mg
  • Particles were also made of the above materials with the addition of 30% by weight ammonia solution in an amount to provide a pH of 8.0-9.0.
  • the active drug, the sucrose, the corn starch and the talcum were blended thoroughly to yield a dusting powder.
  • the non-pareil seeds were loaded into a centrigual coater and then coated with the dusting powder while spraying the HPMC (hydroxypropyl methyl cellulose) solution, with the ammonia solution when used. This resulted in the production of a plurality of discrete particles containing the active ingredient.
  • the particles so obtained were dried using conventional tray dryers/fluid bed dryers to an outlet temp, of 45 °C.
  • a plurality of particles containing the active drug were prepared as follows:
  • Non-pareil seeds 95.00 mg Active drug 20.00 mg Sucrose 32.00 mg Corn starch 32.00 mg Talcum 10.00 mg HPMC 1.00 mg
  • Particles were also made of the above materials with the addition of 3.00 mg ammonium carbonate.
  • the active drug, the sucrose, the corn starch, the ammonium carbonate (when present) and the talcum were blended thoroughly to yield a dusting powder.
  • the non-pareil seeds were loaded into the centrifugal coater and then coated with the dusting powder while spraying the HPMC (hydroxypropyl methyl cellulose) solution. This resulted in the production of a plurality of discrete particles containing the active ingredient.
  • the particles so obtained were dried using conventional tray dryers/fluid bed dryers to an outlet temp, of 45 °C.
  • a plurality of particles containing the active drug were prepared from the following materials:
  • Particles were also made of the above materials but with the addition of 3.00 mg ammonium carbonate.
  • the active drug, the sucrose, the corn starch, the ammonium carbonate (when present) and the talcum were blended thoroughly to yield a dusting powder.
  • the non-pareil seeds were loaded into the centrifugal coater and then coated with the dusting powder while spraying the HPC-L Klucel (hydroxypropyl cellulose) solution. This resulted in the production of a plurality of discrete particles containing the active ingredient.
  • the particles so obtained were dried using conventional tray dryers/fluid bed dryers to an outlet temp, of 45°C.
  • a plurality of tablet cores containing an active drug were prepared from the following materials:
  • Particles were also made of the above materials but with the addition of 30% by weight solution of ammonia to give a pH of 8.0-9.0.
  • the active drug was blended with the sucrose and the corn starch in a suitable mixer.
  • the blend containing the active drug was then granulated with a solution of the gelatine binder (with the ammonia when present).
  • the granules were dried using conventional means, then lubricated with the talcum and magnesium stearate. Finally, the granules were compressed into a suitable shape for a tablet core using conventional compression equipment.
  • a plurality of tablet cores containing an active drug were prepared from the following materials:
  • Particles were also made of the above materials but also including 3.00 mg ammonium carbonate.
  • the active drug was blended with the sucrose, corn starch and the ammonium carbonate (when present) in a suitable mixer.
  • the blend containing the active drug was then granulated with a solution of the gelatine binder.
  • the granules were dried using conventional means, then lubricated with the talcum and magnesium stearate. Finally, the granules were compressed into a suitable shape for a tablet core using conventional compression equipment.
  • Example 7 A plurality of tablet cores containing an active drug were prepared from the following materials:
  • Particles were also made of the above materials but also including 2.00 mg ammonium carbonate.
  • the active drug was blended with the mannitol, and then granulated with a solution of PVP-K30 containing ammonium carbonate (when present).
  • the granules were dried using conventional means, then lubricated with the talcum, magnesium stearate, PEG 6000 and Crospovidone. Finally, the granules were compressed into a suitable shape for a tablet core using conventional compression equipment.
  • Example 8 A plurality of tablet cores containing an active drug were prepared from the following materials:
  • Particles were also made of the above materials but including 30% by weight ammoma solution to a pH of 8.0-9.0.
  • the active drug was blended with the mannitol. It was then granulated with the ammoma solution (when present). The granules were dried using conventional means, then lubricated with the talcum, magnesium stearate, PEG 6000 and Crospovidone. Finally, the granules were compressed into a suitable shape for a tablet core using conventional compression equipment.
  • Intermediate Example 16 The 190.00 mg particles formed in Intermediate Example 5 were coated with 3.00 mg polydimethylsiloxane to produce a moisture resistant coating around each particle.
  • the 190.00 mg particles formed in Intermediate Example 4 were also treated with 20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose along with other conventional coating additives to produce a moisture resistant coating around each particle.
  • the 190.00 mg particles formed in Intermediate Example 5 were also treated with 20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose along with other conventional coating additives to produce a moisture resistant coating around each particle.
  • the 193.00 mg particles formed in Intermediate Example 6 were also treated with 20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose along with other conventional coating additives to produce a moisture resistant coating around each particle.
  • the 190.00 mg particles formed in Intermediate Example 4 were coated with polydimethylsiloxane, and an amount of 30% by wt. ammonia solution, to produce a moisture resistant coating around each particle.
  • the 190.00 mg particles formed in Intermediate Example 5 were coated with polydimethylsiloxane, and an amount of 30% by wt. ammonia solution, to produce a moisture resistant coating around each particle.
  • a plurality of particles containing the active drug were prepared from the following materials:
  • a plurality of particles containing the active drug were made from the following materials:
  • Non-pareil seeds 95.00 mg
  • Particles were also made of the above materials with the addition of 30% by weight solution of ammoma to pH 8.0-9.0.
  • a plurality of particles containing the active drug were prepared from the following materials:
  • Non-pareil seeds 108.00 mg Active drug 20.00 mg Sucrose 35.90 mg Corn Starch 21.10 mg Talcum 2.00 mg
  • Particles were also made of the above materials with the addition of 30% by weight solution of ammonia to pH 8.0-9.0.
  • compositions obtained in Intermediate Examples 1 - 8 and 23, 24, 25 were treated with 11.00 mg of a mixture comprising of 2.85 mg of an emulsion of polydimethylsiloxane with 9.00 mg of a binding agent as described earlier (Sucrose/Polyvinylpyrrolidone/Shellac/Xanthan Gum), along with 1 mg of talc.
  • the coating was carried out using a fluidised bed coater. Alternately, it could have been carried out using a conventional coating pan. This produced a moisture resistant coating around each composition of the respective examples.
  • Example 1 Example 1
  • the particles formed in Intermediate Examples 9 to 14 were provided with an enteric coating to yield compositions according to the present invention. Some were coated with cellulose acetate phthalate, some with HPMCP and some with Eudragit L 100 55. In each case, 500.00 g of the particles were each coated with 55.00 g of the respective enteric coating polymer.
  • the enteric coating polymer was deposited using a conventional coating process.
  • the particles formed in Intermediate Examples 15 to 22 were each coated with an enteric coating polymer to yield tablet compositions according to the present invention. Some were coated with cellulose acetate phthalate, some with HPMCP and some with Euragdit L 100 55. In each case, the enteric coating polymer was deposited using a conventional process for coating.
  • Example 1 500.00 g of the enteric coated particles from Example 1 were coated with 3.00 mg per unit dosage form of a moisture resistant coating of polydimethylsiloxane. The moisture resistant coating was sprayed onto the particles.
  • Example 5 500.00 g of the enteric coated particles from Example 1 were coated with 20.00 mg of an emulsion containing 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose per unit dosage form to give a moisture resistant coating. The moisture resistant coating was sprayed onto the particles.
  • Example 5 500.00 g of the enteric coated particles from Example 1 were coated with 20.00 mg of an emulsion containing 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose per unit dosage form to give a moisture resistant coating. The moisture resistant coating was sprayed onto the particles.
  • Example 2 500.00 g of the enteric coated tablets from Example 2 were each coated with 3.00 mg per unit dosage form of a moisture resistant coating of polydimethylsiloxane. The moisture resistant coating was sprayed onto the tablets.
  • Example 2 500.00 g of the enteric coated tablets from Example 2 were each coated with 20.00 mg of an emulsion containing 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose per unit dosage form to give a moisture resistant coating. The moisture resistant coating was sprayed onto the tablets.
  • Enteric coatings included cellulose acetate phthalate, HPMCP and Euragdit L 100

Abstract

A pharmaceutical composition which is a solid pellet comprising an inert core, a benzimidazole in or on the core, a moisture resistant coating around the core, the moisture resistant coating comprising at least one hydrophobic material, and an enteric coating around the moisture resistant coating.

Description

BENZIMIDAZOLE PHARMACEUTICAL COMPOSITION AND PROCESS OF PREPARATION
The present invention relates to a pharmaceutical composition and to a process of preparation thereof, and more particularly to a pharmaceutical composition containing a benzimidazole.
Benzirnidazole derivatives, such as omeprazole, lansoprazole and timoprazole, etc., are known potent proton pump inhibitors with powerful inhibitory action against the secretion of gastric acid (Lancet, Nov. 27, 1982, pages 1223 - 1224). They are used in the treatment of Zollinger- Ellison syndrome and stress related oesophagitis ulceration. The derivatives are well known and are described, for example, in EP-A-0005129.
It has been found that these benzimidazole derivatives, and in particular omeprazole, are susceptible to degradation in acid and neutral media and it is known to protect oral dosage forms by provision of an enteric coating. In this way, the active material is protected from acidic gastric juices until it reaches the site of desired release, e.g. the small intestine. Because certain enteric coatings can themselves be, or contain, acidic materials it is also often required to protect the benzimidazole from the acidity of the enteric coatings. For example, it is known to formulate the benzimidazole with an alkaline material before applying the enteric coating; it is also known to provide an intermediate coating between the benzimidazole and the enteric coating, generally the intermediate coating is selected so as to be substantially water soluble. EP-A-0247983 describes an oral pharmaceutical preparation of omeprazole which is composed of a core material in the form of small beads or tablets containing omeprazole together with an alkaline reacting compound, the core material having one or more inert reacting subcoating layers thereon. The alkaline reacting compounds can be chosen among but are not restricted to substances such as the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids; substances normally used in antacid preparations such as alurriinium, calcium and magnesium hydroxides; magnesium oxide or composite substances, such as Al203.6MgO.C02.12H20, (Mg6Al2(OH)16C03.4H20), MgO.Al203.2Si02.nH20 or similar compounds; organic pH-buffering substances such as trmydroxymethylaminomethane or other similar, pharmaceutically acceptable pH-buffering substances. The specification further states that if an alkaline reacting salt of omeprazole such as the sodium, potassium, magnesium, calcium or ammonium salt of omeprazole (which are described in EP-A-0124495) is used, this can be in place of or in addition to the alkaline reacting compound.
TW289733 describes a process of preparing pellets containing omeprazole. The process comprises spraying a solution comprising omeprazole, excipient, ethanol, water, ammonia and binder on an inert core; granulating; spraying an intermediate coating solution comprising excipient, ethanol, water, ammonia and binder on the granules; and providing a final outer coating.
US4786505 describes pharmaceutical preparations containing omeprazole in an alkali environment as the core material, one or more inert subcoating layers which are water soluble and an outer enteric coating.
There is however provided by the present invention pharmaceutical compositions, and processes of preparing the same, wherein an active ingredient comprising a benzimidazole can be protected from surrounding acidic media, and the compositions offer further advantages over the prior art by exhibiting extended shelf life. According to the present invention, there is provided a pharmaceutical composition which is a solid pellet comprising an inert core, a benzimidazole in or on the core, a moisture resistant coating around the core, the moisture resistant coating comprising at least one hydrophobic material, and an enteric coating around the moisture resistant coating.
There is further provided by the present invention a process of preparing a composition substantially as described above, which process comprises providing an inert core having a benzimidazole therein or thereon, applying a moisture resistant coating around the core, the moisture resistant coating comprising at least one hydrophobic material, and applying an enteric coating around the moisture resistant coating.
Preferably, the benzimidazole in or on the core is present in an alkaline environment, and more particularly the benzimidazole is present as an intimate mixture with at least one alkali. Suitably, the alkali is ammonia or a solution of ammonia or ammonium carbonate. A process according to the present invention therefore preferably further comprises formulating the benzimidazole in an alkaline environment substantially as herein described.
It is generally preferred that an alkali employed in the present invention comprises an aqueous solution of ammonia (i.e. ammonium hydroxide) or ammonium carbonate, although it is of course also possible to use liquid ammonia or ammonia gas. In such cases, the benzimidazole may be formulated under an ammonia atmosphere, for example, and the gas may be absorbed, such as by dissolution in any aqueous material present.
In accordance with the invention, the pH of the benzimidazole- containing part of any formulation is preferably from above 7 to 10, and is more preferably in the range 8 to 9. Advantageously, an ammonia solution is used, the solution preferably containing from 20 to 40wt% ammonia, more preferably about 30 wt% ammonia. The invention is applicable to pharmaceutically active benzimidazole derivatives. Particularly useful such derivatives are the alkali metal salts of the benzimidazole. Examples of specific useful derivatives are omeprazole, lansoprazole, timoprazole, pariprazole and pantoprazole, in particular omeprazole.
The purpose of the moisture resistant coating employed in the present invention is to resist moisture absorption by the pharmaceutical composition, thereby extending shelf life. Suitably, the hydrophobic material of the coating is present in sufficient amount to ensure that the coating substantially repels water therefrom. The hydrophobic material can be solid or liquid, and is desirably selected from the group consisting of a polyalkylsiloxane, castor oil, mineral oil, isopropyl myristate, stearic acid, cetyl alcohol or the like. Preferably, the hydrophobic material comprises a polyalkylsiloxane, and it is particularly preferred that the hydrophobic material comprises polydimethylsiloxane.
The moisture resistant coating may further comprise at least one binding agent. The binding agent may be hydrophobic or hydrophilic. In the latter case, the binding agent is incorporated in the moisture resistant coating in an amount which ensures that the water repellent properties of the latter (as provided by the hydrophobic material substantially as described above), are substantially unaffected by the hydrophilic nature of the binding agent. The binding agent is preferably selected from the group consisting of a sugar, polyvinyl-pyrrolidone, shellac and gums, such as xanthan gum, or the like. It is especially preferred that the binding agent comprises a sugar, such as sucrose or the like.
Advantageously, a binding agent is employed in the moisture resistant coating when the hydrophobic material is a liquid. A preferred moisture resistant coating comprises an emulsion of a polyalkylsiloxane (especially polydimethylsiloxane) or an admixture thereof, with the binding agent. The moisture resistant coating may contain one or more other conventional additives that typically aid in the process of adhesion onto the inert core.
The moisture resistant coating may also be useful in benzimidazole pharmaceutical compositions that do not have an alkaline binder. The moisture resistant coating can be typically applied by spraying, using conventional equipment. In addition to the moisture resistant coating applied directly to the inert core substantially as hereinbefore described, a further moisture resistant coating can be provided over the enteric coating.
A wide variety of conventional enteric coatings may be employed in the present invention, including for example: cellulose acetate phthalate; hydroxypropyl methyl cellulose phthalate (HPMCP); hydroxypropyl cellulose acetyl succinate; polyvinyl acetate phthalate; copolymerised methacrylic acid/methacrylic acid methyl esters, such as Eudragit L 12-5, Eudragit L 100 55 or Eudragit S 100; and mixtures thereof. The enteric coating may contain conventional plasticisers, pigments and/or dispersants, including for example polyethylene glycols, triacetin, triethyl citrate, and Citroflex, dibutyl sebacate.
The enteric coating can be applied in any suitable manner, for example in the form of an aqueous dispersion in water, or other dispersing medium, or in the form of a solution. It is preferred that a dispersion or solution of the enteric coating is treated with an alkali in order to neutralise at least part of any free acid content. The alkali may be, for example, a carbonate or hydroxide of sodium, potassium, magnesium or calcium.
According to a first embodiment of the present invention, the benzimidazole is present in the inert core. Suitably, the inert core of the pharmaceutical composition comprises a plurality of compressed granules of the benzimidazole. This embodiment is particularly useful when it is desired to provide the pharmaceutical composition in tablet form, and there is further provided by the present invention a tablet which comprises a pharmaceutical composition substantially as herein described, wherein the inert core is formed from a plurality of granules comprising the benzimidazole, which granules are compressed together to form the core.
According to the first embodiment of the present invention, the moisture resistant coating is applied around the inert core, then the enteric coating is suitably provided around the moisture resistant coating on the inert core.
According to a second embodiment of the present invention, the benzimidazole is present on the inert core. The second embodiment of the present invention is particularly applicable for the inclusion of a plurality of pellets substantially as herein before described in a capsule. The inert cores of the pellets may typically be non-pareils, and suitably provided in the form of sugar beads or sugar/starch beads. According to the second embodiment of the present invention there is therefore provided a capsule which comprises a capsule shell containing a plurality of pellets substantially as herein before described.
According to the second embodiment of the present invention, the moisture resistant coating is applied around the inert core of each of the pellets to be provided in a capsule, and the enteric coating is suitably provided around the moisture resistant coating on each of the inert cores.
Pharmaceutical compositions according to the present invention may comprise one or more additives. Examples of particularly useful additives include a solubiliser to aid solubilisation of the pharmaceutically active ingredient, and a lubricant to aid flow of the active ingredient during manufacture. The solubiliser may be, for example, a sugar, which is preferably in pulverised form. An example of a suitable sugar is sucrose. The lubricant may be, for example, starch and/or talcum. It will be appreciated that the pharmaceutical compositions of the invention may contain any one or more other additives conventionally used in the formulation of pharmaceutical compositions.
The pharmaceutical compositions of the invention may be used to treat conditions in the same manner as the prior known benzimidazole compositions. The pharmaceutical compositions may be formulated for oral, topical, parenteral or rectal administration. Oral administration is preferred.
The pharmaceutical compositions may take the form of, for example, a tablet or peltab (e.g. comprising a plurality of granules comprising a benzimidazole, together with conventional excipients, such as disintegrants and binders, compressed into a tablet) or a capsule (e.g. containing a plurality of individual pellets comprising a benzimidazole disposed within the capsule shell). Furthermore, the pharmaceutical composition may include conventional excipients.
Tablets to be employed in compositions of the invention can be made, for example, by using equipment known as a marumerizer (which is also called a spheronizer). In such cases, core ingredients, including the benzimidazole, can be extruded into the marumerizer, and converted into substantially spherical granules by a high speed rotating disk. Subsequently, the granules may be compressed by conventional means in order to form a solid core, and subsequently coated with a moisture resistant coating and an enteric coating as herein before described.
When, alternatively, the pellets comprise benzimidazole loaded onto a plurality of inert cores suitable for inclusion in a capsule, the benzimidazole can be supplied as a spray, for example. The benzimidazole may be mixed with one or more additives before being loaded on the inert cores. As described above, the additives may include, for example, a solubiliser and/or a lubricant. The inert cores can be loaded with the benzimidazole (together with any additives), and sprayed with a binder, in a centrifugal coating apparatus.
The following Intermediate Examples and Examples illustrate the invention. In each case, the active drug was omeprazole unless indicated otherwise. Whilst sucrose (sugar) is the illustrated binding agent, other binding agents such as polyvinylpyrrolidone, shellac or xanthan gum, may be used instead.
Intermediate Example 1 A plurality of particles containing the active drug were prepared from the following materials:
Non-pareil seeds 95.00 mg
Active drug 20.00 mg
Sucrose 32.00 mg
Corn starch 32.00 mg
Talcum 10.00 mg
HPMC 1.00 mg
90.00 mg
Water: as required.
Particles were also made of the above materials with the addition of 30% by weight ammonia solution in an amount to provide a pH of 8.0-9.0.
Initially, the active drug, the sucrose, the corn starch and the talcum were blended thoroughly to yield a dusting powder. The non-pareil seeds were loaded into a centrigual coater and then coated with the dusting powder while spraying the HPMC (hydroxypropyl methyl cellulose) solution, with the ammonia solution when used. This resulted in the production of a plurality of discrete particles containing the active ingredient. The particles so obtained were dried using conventional tray dryers/fluid bed dryers to an outlet temp, of 45 °C.
Intermediate Example 2
A plurality of particles containing the active drug were prepared as follows:
Non-pareil seeds 95.00 mg Active drug 20.00 mg Sucrose 32.00 mg Corn starch 32.00 mg Talcum 10.00 mg HPMC 1.00 mg
90.00 mg
Water: as required.
Particles were also made of the above materials with the addition of 3.00 mg ammonium carbonate.
Initially, the active drug, the sucrose, the corn starch, the ammonium carbonate (when present) and the talcum were blended thoroughly to yield a dusting powder. The non-pareil seeds were loaded into the centrifugal coater and then coated with the dusting powder while spraying the HPMC (hydroxypropyl methyl cellulose) solution. This resulted in the production of a plurality of discrete particles containing the active ingredient. The particles so obtained were dried using conventional tray dryers/fluid bed dryers to an outlet temp, of 45 °C.
Intermediate Example 3
A plurality of particles containing the active drug were prepared from the following materials:
Non-pareil seeds 108.00 mg
Active drug 20.00 mg
Sucrose 35.90 mg
Corn starch 21.10 mg
Talcum 2.00 mg HPC-L Klucel . 1.00 mg
186.00 mg
Water: as required.
Particles were also made of the above materials but with the addition of 3.00 mg ammonium carbonate.
Initially, the active drug, the sucrose, the corn starch, the ammonium carbonate (when present) and the talcum were blended thoroughly to yield a dusting powder. The non-pareil seeds were loaded into the centrifugal coater and then coated with the dusting powder while spraying the HPC-L Klucel (hydroxypropyl cellulose) solution. This resulted in the production of a plurality of discrete particles containing the active ingredient. The particles so obtained were dried using conventional tray dryers/fluid bed dryers to an outlet temp, of 45°C.
Intermediate Example 4
A plurality of tablet cores containing an active drug were prepared from the following materials:
Sucrose 80.00 mg
Cora Starch 86.00 mg
Active drug 20.00 mg
Talcum 1.00 mg
Magnesium stearate 1.00 mg
Gelatine 2.00 mg
190.00 mg Water: as required
Particles were also made of the above materials but with the addition of 30% by weight solution of ammonia to give a pH of 8.0-9.0.
Initially the active drug was blended with the sucrose and the corn starch in a suitable mixer. The blend containing the active drug was then granulated with a solution of the gelatine binder (with the ammonia when present). The granules were dried using conventional means, then lubricated with the talcum and magnesium stearate. Finally, the granules were compressed into a suitable shape for a tablet core using conventional compression equipment.
Intermediate Example 5
Employing the same procedure of Intermediate Example 4, tablet cores were also made of the following composition:
Sucrose 45.00 mg
Dicalcium phosphate 75.00 mg
Corn starch 45.00 mg
Active drug 20.00 mg
Talcum 1.00 mg
Magnesium stearate 2.00 mg
Gelatine 2.00 mg
190.00 mg
Water: as required Particles were also made of the above materials but with the addition of 30% by weight solution of ammonia to a pH of 8.0-9.0.
Intermediate Example 6
A plurality of tablet cores containing an active drug were prepared from the following materials:
Sucrose 80.00 mg
Corn Starch 86.00 mg
Active drug 20.00 mg
Talcum 1.00 mg
Magnesium stearate 1.00 mg
Gelatine 2.00 mg
190.00 mg
Water: as required
Particles were also made of the above materials but also including 3.00 mg ammonium carbonate.
Initially the active drug was blended with the sucrose, corn starch and the ammonium carbonate (when present) in a suitable mixer. The blend containing the active drug was then granulated with a solution of the gelatine binder. The granules were dried using conventional means, then lubricated with the talcum and magnesium stearate. Finally, the granules were compressed into a suitable shape for a tablet core using conventional compression equipment.
Intermediate Example 7 A plurality of tablet cores containing an active drug were prepared from the following materials:
Active drug 20.00 mg
Mannitol 115.50 mg
Polyvinylpyrrolidone K30 4.00 mg
Crospovidone 7.00 mg
Magnesium stearate 3.00 mg
Talcum 1.50 mg
Polyethylene Glycol 2.00 mg 6000
153.00 mg
Water: as required
Particles were also made of the above materials but also including 2.00 mg ammonium carbonate.
The active drug was blended with the mannitol, and then granulated with a solution of PVP-K30 containing ammonium carbonate (when present). The granules were dried using conventional means, then lubricated with the talcum, magnesium stearate, PEG 6000 and Crospovidone. Finally, the granules were compressed into a suitable shape for a tablet core using conventional compression equipment.
Intermediate Example 8 A plurality of tablet cores containing an active drug were prepared from the following materials:
Active drug 20.00 mg
Mannitol 115.50 mg
Polyvinylpyrrolidone K30 4.00 mg
Crospovidone 7.00 mg
Magnesium stearate 3.00 mg
Talcum 1.50 mg
Polyethylene Glycol 2.00 mg 6000
153.00 mg
Water: as required
Particles were also made of the above materials but including 30% by weight ammoma solution to a pH of 8.0-9.0.
The active drug was blended with the mannitol. It was then granulated with the ammoma solution (when present). The granules were dried using conventional means, then lubricated with the talcum, magnesium stearate, PEG 6000 and Crospovidone. Finally, the granules were compressed into a suitable shape for a tablet core using conventional compression equipment.
Intermediate Example 9
190.00 mg of the particles of the composition formed in Intermediate Example 1 were treated with 3.00 mg of polydimethylsiloxane, and as much water as necessary. The coating was carried out using a conventional coating pan. Instead, it could have been carried out using a fluidised bed coater. This produced a moisture resistant coating around the particles of the composition of Intermediate Example 1.
Intermediate Example 10
190.00 mg of the particles of the composition formed in Intermediate Example 1 were also treated with 20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose along with other conventional coating additives. The coating was carried out using a conventional coating pan. Instead, it could have been carried out using a fluidised bed coater. This produced a moisture resistant coating around the particles of the composition of Intermediate Example 1.
Intermediate Example 11
193.00 mg of the particles of the composition formed in Intermediate Example 2 were also treated with 20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose along with other conventional coating additives. The coating was carried out using a conventional coating pan. Instead, it could have been carried out using a fluidised bed coater. This produced a moisture resistant coating around the particles of the composition of Intermediate Example 2.
Intermediate Example 12
189.00 mg of the particles of the composition formed in Intermediate Example 3 were treated with 3.00 mg of polydimethylsiloxane, and as much water as necessary. The coating was carried out using a conventional coating pan. Instead, it could have been carried out using a fluidised bed coater. This produced a moisture resistant coating around the particles of the composition of Intermediate Example 3.
Intermediate Example 13
189.00 mg of the particles of the composition formed in Intermediate Example 3 were also treated with 20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose along with other conventional coating additives. The coating was carried out using a conventional coating pan. Instead, it could have been carried out using a fluidised bed coater. This produced a moisture resistant coating around the particles of the composition of Intermediate Example 3.
Intermediate Example 14
Intermediate Example 9 was repeated, using an amount of 30% by wt. ammoma solution, in addition to the polydimethylsiloxane. This produced a moisture resistant coating around the particles of the composition of Intermediate Example 1.
Intermediate Example 15
The 190.00 mg particles formed in Intermediate Example 4 were coated with 3.00 mg polydimethylsiloxane to produce a moisture resistant coating around each particle.
Intermediate Example 16 The 190.00 mg particles formed in Intermediate Example 5 were coated with 3.00 mg polydimethylsiloxane to produce a moisture resistant coating around each particle.
Intermediate Example 17
The 190.00 mg particles formed in Intermediate Example 4 were also treated with 20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose along with other conventional coating additives to produce a moisture resistant coating around each particle.
Intermediate Example 18
The 190.00 mg particles formed in Intermediate Example 5 were also treated with 20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose along with other conventional coating additives to produce a moisture resistant coating around each particle.
Intermediate Example 19
The 193.00 mg particles formed in Intermediate Example 6 were coated with 3.00 mg polydimethylsiloxane to produce a moisture resistant coating around each particle.
Intermediate Example 20
The 193.00 mg particles formed in Intermediate Example 6 were also treated with 20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose along with other conventional coating additives to produce a moisture resistant coating around each particle.
Intermediate Example 21
The 190.00 mg particles formed in Intermediate Example 4 were coated with polydimethylsiloxane, and an amount of 30% by wt. ammonia solution, to produce a moisture resistant coating around each particle.
Intermediate Example 22
The 190.00 mg particles formed in Intermediate Example 5 were coated with polydimethylsiloxane, and an amount of 30% by wt. ammonia solution, to produce a moisture resistant coating around each particle.
Intermediate Example 23
A plurality of particles containing the active drug were prepared from the following materials:
Non-pareil seeds 108.00 mg
Active drug 20.00 mg
HPMC 10.00 mg
Polyvinylpyrrolidone 4.00 mg
Talcum 2.50 mg
Water As required
Total 144.50 mg Initially, the polyvinylpyrrolidone and HPMC were dissolved in water, to obtain a clear solution. To this solution were added the active drug and talcum, in that order, and dispersed well. This drug suspension was sprayed onto the non-pareil seeds using a fluidised bed coater to obtain drug-loaded cores. These cores were then given a moisture resistant coating in the same way as described in Intermediate Example 9 or 10. Also, an addition of 30% by weight ammonia solution can be used as in Intermediate Example 14.
Intermediate Example 24
A plurality of particles containing the active drug were made from the following materials:
Non-pareil seeds 95.00 mg
Active drug 20.00 mg
Sucrose 30.00 mg
Corn Starch 30.00 mg
Talcum 10.00 mg
Polyvinylpyrrolidone 4.00 mg
HPMC 1.00 mg
Water As required
Total 190.00 mg
Particles were also made of the above materials with the addition of 30% by weight solution of ammoma to pH 8.0-9.0.
The procedure used was as in Intermediate Example 1, the PVP being included in the dusting powder. Intermediate Example 25
A plurality of particles containing the active drug were prepared from the following materials:
Non-pareil seeds 108.00 mg Active drug 20.00 mg Sucrose 35.90 mg Corn Starch 21.10 mg Talcum 2.00 mg
Polyvinylpyrrolidone 4.00 mg HPC-L Klucel 1.00 mg Water As required
Total 192.00 mg
Particles were also made of the above materials with the addition of 30% by weight solution of ammonia to pH 8.0-9.0.
The procedure used was as in Intermediate Example 1, the PVP being included in the dusting powder.
Intermediate Example 26
The compositions obtained in Intermediate Examples 1 - 8 and 23, 24, 25 were treated with 11.00 mg of a mixture comprising of 2.85 mg of an emulsion of polydimethylsiloxane with 9.00 mg of a binding agent as described earlier (Sucrose/Polyvinylpyrrolidone/Shellac/Xanthan Gum), along with 1 mg of talc. The coating was carried out using a fluidised bed coater. Alternately, it could have been carried out using a conventional coating pan. This produced a moisture resistant coating around each composition of the respective examples. Example 1
In this Example, the particles formed in Intermediate Examples 9 to 14 were provided with an enteric coating to yield compositions according to the present invention. Some were coated with cellulose acetate phthalate, some with HPMCP and some with Eudragit L 100 55. In each case, 500.00 g of the particles were each coated with 55.00 g of the respective enteric coating polymer. The enteric coating polymer was deposited using a conventional coating process.
Example 2
In this Example, the particles formed in Intermediate Examples 15 to 22 were each coated with an enteric coating polymer to yield tablet compositions according to the present invention. Some were coated with cellulose acetate phthalate, some with HPMCP and some with Euragdit L 100 55. In each case, the enteric coating polymer was deposited using a conventional process for coating.
Example 3
500.00 g of the enteric coated particles from Example 1 were coated with 3.00 mg per unit dosage form of a moisture resistant coating of polydimethylsiloxane. The moisture resistant coating was sprayed onto the particles.
Example 4
500.00 g of the enteric coated particles from Example 1 were coated with 20.00 mg of an emulsion containing 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose per unit dosage form to give a moisture resistant coating. The moisture resistant coating was sprayed onto the particles. Example 5 -
500.00 g of the enteric coated tablets from Example 2 were each coated with 3.00 mg per unit dosage form of a moisture resistant coating of polydimethylsiloxane. The moisture resistant coating was sprayed onto the tablets.
Example 6
500.00 g of the enteric coated tablets from Example 2 were each coated with 20.00 mg of an emulsion containing 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose per unit dosage form to give a moisture resistant coating. The moisture resistant coating was sprayed onto the tablets.
Example 7
The enteric coated particles of Examples 1 and 2 were respectively employed in the following formulae:
Particles 193.00 mg
Microcrystalline 20.00 mg
Cellulose
Starch 50.00 mg
Talcum 1.00 mg
Particles 189.00 mg
Microcrystalline 20.00 mg
Cellulose
Starch 50.00 mg
Talcum 1.00 mg The particles were intimately mixed with the other ingredients in a suitable mixer. The resultant blend was made into peltabs which were subsequently respectively provided with a moisture resistant and an enteric coating as follows.
Moisture Resistant Coatings
3.00 mg polydimethylsiloxane (optionally with 30% ammonia solution) to produce a moisture resistant coating around each particle; or
20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose, along with other conventional coating additives to produce a moisture resistant coating around each particle.
Enteric Coatings
Enteric coatings included cellulose acetate phthalate, HPMCP and Euragdit L 100
55.
It will appreciated that modifications may be made to the invention described above.

Claims

CLAIMS:
1. A pharmaceutical composition which is a solid pellet comprising an inert core, a benzimidazole in or on the core, a moisture resistant coating around the core, the moisture resistant coating comprising at least one hydrophobic material, and an enteric coating around the moisture resistant coating.
2. A composition according to claim 1, wherein the benzimidazole is omeprazole, lansoprazole, timoprazole, pariprazole or pantoprazole.
3. A composition according to claim 2, wherein the benzimidazole is omeprazole.
4. A composition according to any of claims 1 to 3, wherein the hydrophobic material is selected from the group consisting of a polyalkylsiloxane, castor oil, mineral oil, isopropyl myristate, stearic acid and cetyl alcohol.
5. A composition according to claim 4, wherein the hydrophobic material comprises a polyalkylsiloxane.
6. A composition according to claim 5, wherein the polyalkylsiloxane is polydimethylsiloxane.
7. A pharmaceutical composition which is a solid pellet comprising an inert core, a benzimidazole in or on the core, a moisture resistant coating around the core, the moisture resistant coating comprising at least one hydrophobic material, and an enteric coating around the moisture resistant coating, wherein the benzimidazole is omeprazole, and the moisture resistant coating comprises a polyalkylsiloxane.
8. A composition according to claim 7, wherein the polyalkylsiloxane is polydimethylsiloxane.
9. A composition according to any of claims 1 to 8, wherein the moisture resistant coating further comprises at least one binding agent.
10. A composition according to claim 9, wherein the binding agent is selected from the group consisting of a sugar, polyvinyl-pyrrolidone, shellac and xanthan gum.
11. A composition according to claim 10, wherein the binding agent comprises a sugar.
12. A composition according to any of claims 1 to 11, wherein the benzimidazole in or on the core is in an alkaline environment.
13. A composition according to claim 12, wherein the benzimidazole is present as an intimate mixture with at least one alkali.
14. A composition according to claim 13, wherein the benzimidazole is present as an intimate mixture with ammonia, ammonium hydroxide or ammonium carbonate.
15. A composition according to claim 14, wherein the benzimidazole is present as an intimate mixture with ammonium carbonate.
16. A tablet which comprises a pharmaceutical composition according to any of claims 1 to 15, wherein the inert core is formed from a plurality of granules comprising the benzimidazole, which granules are compressed together to form the core.
17. A capsule which comprises a capsule shell containing a plurality of pellets as provided by a pharmaceutical composition according to any of claims 1 to 15, wherein the benzimidazole is present on the inert core.
18. A process of preparing a composition according to claim 1, which process comprises providing an inert core having a benzimidazole in or on the core, applying a moisture resistant coating around the core, the moisture resistant coating comprising at least one hydrophobic material, and applying an enteric coating around the moisture resistant coating.
19. A process according to claim 18, wherein the benzimidazole is formulated in an alkaline environment.
20. A process according to claim 19, wherein the benzimidazole is formulated in the presence of ammonia, ammonium hydroxide or ammonium carbonate.
21. A process according to claim 20, wherein the benzimidazole is formulated in the presence of ammonium carbonate.
22. A process according to any of claims 18 to 21, wherein the hydrophobic material comprises a polyalkylsiloxane.
23. A process according to claim 22, wherein the polyalkylsiloxane is polydimethylsiloxane.
24. A process according to any of claims 18 to 23, wherein the benzimidazole is omeprazole, lansoprazole, timoprazole, pariprazole or pantoprazole.
25. A process according to claim 24, wherein the benzimidazole is omeprazole.
26. A process of preparing a tablet according to claim 16, which process comprises compressing together a plurality of the granules to form the core, applying the moisture resistant coating to the core and applying the enteric coating to the moisture resistant coating.
27. A process of preparing a capsule according to claim 17, which process comprises providing the benzimidazole on the inert core, applying the moisture resistant coating thereto, applying the enteric coating to the moisture resistant coating, so as to provide a plurality of pellets as provided by a pharmaceutical composition according to claim 1, and enclosing the pellets in a capsule shell.
EP98922927A 1997-05-23 1998-05-21 Benzimidazole pharmaceutical composition and process of preparation Withdrawn EP0983067A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9710800.5A GB9710800D0 (en) 1997-05-23 1997-05-23 Pharmaceutical composition and method of preparing it
GB9710800 1997-05-23
PCT/GB1998/001465 WO1998052564A1 (en) 1997-05-23 1998-05-21 Benzimidazole pharmaceutical composition and process of preparation

Publications (1)

Publication Number Publication Date
EP0983067A1 true EP0983067A1 (en) 2000-03-08

Family

ID=10813043

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98922927A Withdrawn EP0983067A1 (en) 1997-05-23 1998-05-21 Benzimidazole pharmaceutical composition and process of preparation

Country Status (6)

Country Link
EP (1) EP0983067A1 (en)
AU (1) AU729038B2 (en)
CA (1) CA2290824A1 (en)
GB (2) GB9710800D0 (en)
WO (1) WO1998052564A1 (en)
ZA (1) ZA984266B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136249A0 (en) 1997-12-08 2001-05-20 Byk Gulden Lomberg Chem Fab Suppository containing an acid-labile active compound
FR2774288B1 (en) 1998-01-30 2001-09-07 Ethypharm Sa GASTROPROTEGED OMEPRAZOLE MICROGRANULES, PROCESS FOR OBTAINING AND PHARMACEUTICAL PREPARATIONS
FR2793688B1 (en) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques GASTROPROTEGED MICROGRANULES, PROCESS FOR OBTAINING AND PHARMACEUTICAL PREPARATIONS
EA005803B1 (en) 1999-06-07 2005-06-30 Алтана Фарма Аг Novel preparation and administration form comprising an acid-labile active compound
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
ES2168043B1 (en) 1999-09-13 2003-04-01 Esteve Labor Dr PHARMACEUTICAL FORM ORAL SOLID MODIFIED RELEASE CONTAINING A COMPOSITE OF BENCIMIDAZOL LABIL IN THE MIDDLE ACID.
AR021347A1 (en) 1999-10-20 2002-07-17 Cipla Ltd A PHARMACEUTICAL COMPOSITION CONTAINING SISPHOSPHONIC ACID (S) OR SALT (S) OF THE SAME AND A PREPARATION PROCESS OF THE SAME
EP1222922B1 (en) * 1999-10-20 2007-08-15 Eisai R&D Management Co., Ltd. Method for stabilizing benzimidazole compounds
AU2127200A (en) * 1999-11-02 2001-05-14 Cipla Limited A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereofand a process of preparing thereof
DE19959419A1 (en) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stable pharmaceutical preparations comprising a benzimidazole and process for their preparation
AU2004216405A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Stable pharmaceutical composition of rabeprazole and processes for their preparation
EP1696889A1 (en) * 2003-08-28 2006-09-06 Ranbaxy Laboratories, Ltd. Pharmaceutical compositions of benzimidazole and processes for their preparation
EP1667681A4 (en) * 2003-10-03 2009-09-30 Astron Res Pvt Ltd A novel transmucosal delivery system
SI1746980T1 (en) 2004-05-07 2012-03-30 Nycomed Gmbh Pharmaceutical dosage form comprising pellets as well as its manufacturing process
WO2006011159A2 (en) * 2004-06-21 2006-02-02 Torrent Pharmaceuticals Limited Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability
ITMI20062290A1 (en) * 2006-11-28 2008-05-29 Monteres S R L TABLETS STABLE WITH STORAGE BASED ON BENZIMIDAZOLE DERIVATIVES COATED WITH GASTRO-RESISTANT FILM
CN101822671A (en) * 2009-03-06 2010-09-08 信谊药厂 Rabeprazde composition and preparation method thereof
CN103202818A (en) * 2012-01-15 2013-07-17 山东新时代药业有限公司 An enteric-coated tablet containing D-rabeprazole or a pharmaceutically acceptable salt thereof, and a preparation method therefor
CN102772387B (en) * 2012-08-09 2014-02-12 广东帅广医药有限公司 Lansoprazole composition enteric capsule and preparation method thereof
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5920219A (en) * 1982-07-26 1984-02-01 Shin Etsu Chem Co Ltd Preparation of enteric coated pharmaceutical
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (en) * 1988-05-18 1995-07-26 エーザイ株式会社 Oral formulation of acid labile compounds
AU6998796A (en) * 1995-09-21 1997-04-28 Pharma Pass Llc Novel composition containing an acid-labile benzimidazole and process for its preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9852564A1 *

Also Published As

Publication number Publication date
AU729038B2 (en) 2001-01-25
WO1998052564A1 (en) 1998-11-26
AU7539098A (en) 1998-12-11
CA2290824A1 (en) 1998-11-26
GB2343117B (en) 2001-07-25
GB9710800D0 (en) 1997-07-23
GB9927132D0 (en) 2000-01-12
GB2343117A (en) 2000-05-03
ZA984266B (en) 1999-01-20

Similar Documents

Publication Publication Date Title
AU729038B2 (en) Benzimidazole pharmaceutical composition and process of preparation
JP3881377B2 (en) Novel formulations and methods
EP0814783B1 (en) Multiple unit effervescent dosage forms comprising protonpump inhibitor
EP1010423B1 (en) Oral pharmaceutical preparation comprising an antiulcer benzimidazole derivative, and process for its production
EP1185254B1 (en) Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
EP0813424B2 (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
US6132771A (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
CA2290531C (en) Pharmaceutical formulation of omeprazole
EP0502556B1 (en) Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of acid labile compounds
JPH09511767A (en) Novel oral pharmaceutical use form
JPH09502740A (en) Multiple unit formulations containing proton pump inhibitors
US20010053387A1 (en) Benzimidazole pharmaceutical composition and process of prepatation
WO2005034924A1 (en) Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
WO2004098573A1 (en) An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
AU695774C (en) New pharmaceutical formulation and process

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021203

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1023059

Country of ref document: HK